BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 34889947)

  • 1. A Comparison of Clinicopathologic Outcomes Across Neoadjuvant and Adjuvant Treatment Modalities in Resectable Gastric Cancer.
    Anderson E; LeVee A; Kim S; Atkins K; Guan M; Placencio-Hickok V; Moshayedi N; Hendifar A; Osipov A; Gangi A; Burch M; Waters K; Cho M; Klempner S; Chao J; Kamrava M; Gong J
    JAMA Netw Open; 2021 Dec; 4(12):e2138432. PubMed ID: 34889947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of treatment modalities in non-metastatic gastric adenocarcinoma: a propensity score matching analysis of the National Cancer Database.
    Barzi A; Yang D; Kim AW; Shah MA; Sadeghi S
    BMJ Open Gastroenterol; 2020 Nov; 7(1):. PubMed ID: 33148789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant Chemotherapy Is Associated With Improved Overall Survival in Locally Advanced Rectal Cancer After Achievement of a Pathologic Complete Response to Chemoradiation.
    Shahab D; Gabriel E; Attwood K; Ma WW; Francescutti V; Nurkin S; Boland PM
    Clin Colorectal Cancer; 2017 Dec; 16(4):300-307. PubMed ID: 28420585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy.
    Badgwell B; Blum M; Estrella J; Chiang YJ; Das P; Matamoros A; Fournier K; Mansfield P; Ajani J
    J Am Coll Surg; 2015 Jul; 221(1):83-90. PubMed ID: 26002780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage II/III rectal adenocarcinomas: Analysis of the National Cancer Data base.
    Cassidy RJ; Liu Y; Patel K; Zhong J; Steuer CE; Kooby DA; Russell MC; Gillespie TW; Landry JC
    Cancer; 2017 Mar; 123(5):783-793. PubMed ID: 27780316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer: A Post Hoc Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.
    Diefenhardt M; Ludmir EB; Hofheinz RD; Ghadimi M; Minsky BD; Rödel C; Fokas E
    JAMA Oncol; 2020 Sep; 6(9):1416-1421. PubMed ID: 32644104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
    Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
    [No Abstract]   [Full Text] [Related]  

  • 8. [A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data].
    Ding XW; Zheng ZC; Zhao Q; Zhai G; Liang H; Wu X; Zhu ZG; Wang HJ; He QS; He XL; Du YA; Chen LC; Hua YW; Huang CM; Xue YW; Zhou Y; Zhou YB; Wu D; Fang XD; Dai YG; Zhang HW; Cao JQ; Li LP; Chai J; Tao KX; Li GL; Jie ZG; Ge J; Xu ZF; Zhang WB; Li QY; Zhao P; Ma ZQ; Yan ZL; Zheng GL; Yan Y; Tang XL; Zhou X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):403-412. PubMed ID: 34000769
    [No Abstract]   [Full Text] [Related]  

  • 9. No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base.
    Al-Sukhni E; Gabriel E; Attwood K; Kukar M; Nurkin SJ; Hochwald SN
    J Am Coll Surg; 2016 Dec; 223(6):784-792.e1. PubMed ID: 27641320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of perioperative and histopathologic outcomes among neoadjuvant treatment strategies for locoregional gastric cancer.
    Janczewski LM; Logan CD; Vitello DJ; Buchheit JT; Abad JD; Bentrem DJ; Chawla A
    J Surg Oncol; 2024 Mar; 129(3):481-488. PubMed ID: 37986548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Propensity Score Analysis of Chemotherapy Use in Patients With Resectable Gallbladder Cancer.
    Ozer M; Goksu SY; Sanford NN; Porembka M; Khurshid H; Ahn C; Maxwell MC; Beg MS; Kazmi SM
    JAMA Netw Open; 2022 Feb; 5(2):e2146912. PubMed ID: 35171262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative chemotherapy versus adjuvant chemotherapy strategies in resectable gastric and gastroesophageal cancer: A Markov decision analysis.
    Choi M; Ishizawa S; Kraemer D; Sasson A; Feinberg E
    Eur J Surg Oncol; 2022 Feb; 48(2):403-410. PubMed ID: 34446344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Tumor-Associated Collagen Signature With Prognosis and Adjuvant Chemotherapy Benefits in Patients With Gastric Cancer.
    Chen D; Chen H; Chi L; Fu M; Wang G; Wu Z; Xu S; Sun C; Xu X; Lin L; Cheng J; Jiang W; Dong X; Lu J; Zheng J; Chen G; Li G; Zhuo S; Yan J
    JAMA Netw Open; 2021 Nov; 4(11):e2136388. PubMed ID: 34846524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing outcomes following total neoadjuvant therapy and following neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer.
    Zhu S; Brodin NP; English K; Ohri N; Chuy JW; Rajdev LN; Narang R; Kalnicki S; Guha C; Garg MK; Kabarriti R
    EClinicalMedicine; 2019 Nov; 16():23-29. PubMed ID: 31832617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
    [No Abstract]   [Full Text] [Related]  

  • 16. Survival Outcomes and Patterns of Care for Stage II or III Resected Gastric Cancer by Race and Ethnicity.
    Wu SP; Keshavjee SH; Yoon SS; Kwon S
    JAMA Netw Open; 2023 Dec; 6(12):e2349026. PubMed ID: 38127346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Three-Drug Induction Chemotherapy Followed by Preoperative Chemoradiation in Patients with Localized Gastric Adenocarcinoma.
    Mizrak Kaya D; Nogueras González GM; Harada K; Blum Murphy MA; Lee JH; Bhutani MS; Weston B; Thomas I; Rogers JE; Das P; Badgwell BD; Ajani JA
    Oncology; 2020; 98(8):542-548. PubMed ID: 32434189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

  • 19. Association of Timing of Adjuvant Therapy With Survival in Patients With Resected Stage I to II Pancreatic Cancer.
    Ma SJ; Oladeru OT; Miccio JA; Iovoli AJ; Hermann GM; Singh AK
    JAMA Netw Open; 2019 Aug; 2(8):e199126. PubMed ID: 31411712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing of surgery after neoadjuvant chemotherapy for gastric cancer: Impact on outcomes.
    Liu Y; Zhang KC; Huang XH; Xi HQ; Gao YH; Liang WQ; Wang XX; Chen L
    World J Gastroenterol; 2018 Jan; 24(2):257-265. PubMed ID: 29375211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.